Origin
W26AI for safer cell & gene therapies
AI and Data for Cell & Gene therapies
Designing novel regulatory DNA (e.g., enhancers and promoters) to program precise therapeutic gene expression patterns - for diseases like cancer, CNS disorders and more. We're building the largest proprietary dataset of synthetic regulatory sequences across diverse cell-states.
Creating the largest patient-derived cancer single-cell dataset for licensing to pharmaceutical and AI companies. These datasets are unique as they rely on precise engineering of tumor and immune cells using our AI designed DNA switches.
Origin shifted from designing regulatory DNA sequences for therapeutic gene expression (therapeutic engineering) to creating and licensing large-scale, patient-derived cancer single-cell datasets, leveraging their DNA engineering tech. The core product has changed from DNA sequence design for therapy to proprietary single-cell data as a licensable asset.